US 12,246,075 B2
Granzyme B directed imaging and therapy
Umar Mahmood, Winchester, MA (US); Benjamin Larimer, Woburn, MA (US); and Eric Wehrenberg-Klee, Boston, MA (US)
Assigned to The General Hospital Corporation, Boston, MA (US)
Filed by The General Hospital Corporation, Boston, MA (US)
Filed on Jan. 5, 2023, as Appl. No. 18/150,542.
Application 18/150,542 is a continuation of application No. 16/314,134, granted, now 11,559,590, previously published as PCT/US2017/040212, filed on Jun. 30, 2017.
Claims priority of provisional application 62/435,541, filed on Dec. 16, 2016.
Claims priority of provisional application 62/357,845, filed on Jul. 1, 2016.
Prior Publication US 2023/0338588 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/08 (2006.01); A61B 5/00 (2006.01); A61K 51/04 (2006.01); A61K 51/10 (2006.01); A61P 35/00 (2006.01); C12Q 1/02 (2006.01); C12Q 1/34 (2006.01); C12Q 1/37 (2006.01); A61B 6/03 (2006.01)
CPC A61K 51/08 (2013.01) [A61B 5/00 (2013.01); A61K 51/0468 (2013.01); A61K 51/1075 (2013.01); A61P 35/00 (2018.01); C12Q 1/02 (2013.01); C12Q 1/34 (2013.01); C12Q 1/37 (2013.01); A61B 5/0033 (2013.01); A61B 5/41 (2013.01); A61B 5/444 (2013.01); A61B 6/037 (2013.01); A61B 2503/40 (2013.01)] 20 Claims
 
1. A compound of Formula I:
A—B—C(I), or a pharmaceutically acceptable salt thereof, wherein:
A comprises a chelating agent;
B is an optional linking group; and
C is a peptide that binds granzyme B, wherein the peptide comprises the amino acid sequence of beta-AGGGIEPD (SEQ ID NO: 22).